Status and phase
Conditions
Treatments
About
This is a phase III clinical trial to evaluate the efficacy and safety of BPI-16350 in combination with Fulvestrant versus placebo combined with Fulvesrant in Patients who have HR positive and HER2 negative locally advanced,recurrent or metastatic breast cancer with disease progression following endocrine therapy.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
274 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Shuseng Wang, Ph.D; Xichun Hu, Ph.D
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal